THE INFLUENCE OF DIETARY SALT AND PLASMA-RENIN ACTIVITY ON MYOSIN HEAVY-CHAIN GENE-EXPRESSION IN RAT HEARTS

被引：15

作者：

BUTTRICK, P

KAPLAN, M

CAMARGO, MJF

DESIMONE, G

LARAGH, JH

WALLERSON, D

DEVEREUX, RB

机构：

[1] Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

[2] The New York Hospital, Cornell Medical Center, New York, NY

[3] Division of Cardiology, Montefiore Medical Center, Bronx, NY, 10467

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1993年 / 6卷 / 07期

关键词：

RENIN; ANGIOTENSIN; MYOSIN; CARDIAC HYPERTROPHY;

D O I：

10.1093/ajh/6.7.579

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The renin - angiotensin system has been implicated as a possible mediator of the cardiac adaptations that develop in response to chronic pressure overload. In order to explore this, we studied rats that had elevated plasma renin activity (PRA) secondary to 6 weeks of either dietary salt restriction or renovascular hypertension (Htn) - conditions that exert distinctly different loads on the myocardium. Separate groups of sham and Htn animals were maintained on a high salt diet that resulted in a relative (Htn) or absolute (sham) reduction in PRA. Heart weight and heart/body weight ratios were increased only in animals with Htn. The ratio of alpha/beta myosin heavy chain (MHC) mRNA was significantly decreased with Htn. This ratio was markedly increased with low salt and was not influenced by high salt intake. Thus, the circulating renin-angiotensin system does not appear to play a primary role in defining cardiac myosin heavy chain adaptations to hemodynamic loads. However, sodium restriction, either via its hemodynamic or humoral effects, is sufficient to induce a physiologic change in myosin heavy chain gene expression in rats.

引用

页码：579 / 585

页数：7

共 46 条

[1]

Nadal-Ginard B., Mahdavi V., Molecular basis of cardiac performance, J Clin Invest, 84, pp. 1693-1700, (1989)

[2]

Scheuer J., Malhotra A., Hirsch C., Physiologic cardiac hypertrophy corrects contractile protein abnormalities associated with pathologic hypertrophy in rats, J Clin Invest, 70, pp. 1300-1305, (1982)

[3]

Izumo S., Lompre A.-M., Matsuoka R., Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy, J Clin Invest, 79, (1987)

[4]

Hammond J.W., Devereux R.B., Alderman M.H., Laragh J., The prevalence and correlates of échocardiographie left ventricular hypertrophy among employed patients with uncomplicated hypertension, J am Coll Cardiol, 7, pp. 639-650, (1986)

[5]

Devereux R.B., Pickering R., Harshfield G.A., Left ventricular hypertrophy in patients with hypertension: Importance of blood pressure response to regularly recurring stress, Circulation, 68, pp. 470-476, (1983)

[6]

Sen S., Tarazi R.C., Bumpus F.M., Cardiac hypertrophy and anti-hypertensive therapy, Cardiovasc Res, 11, pp. 427-433, (1977)

[7]

Alderman E.L., Harrison D.C., Myocardial hypertrophy re* suiting from low dosage isoproterenol administration in rats, Proc Soc Exp Biol Med, 64, pp. 75-78, (1971)

[8]

Ostman-Smith I., Cardiac sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy, Clin Sci, 61, pp. 265-272, (1981)

[9]

Griffin S.A., Brown W., Macpherson F., Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism, Hypertension, 17, pp. 626-635, (1991)

[10]

Jin M., Wilhelm M.J., Lang R.E., The endogenous tissue renin-angiotensin systems: From molecular biology to therapy, Am J Med, 84, pp. 28-36, (1987)

← 1 2 3 4 5 →